PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26633263-7	2016	Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine.	Rosuvastatin Calcium	10-22	interleukin 10	Rattus norvegicus	291-296	
33917884-7	2021	Rosuvastatin/Lactobacillus showed prominent anti-inflammatory effects as revealed by the IL-10/IL-12 ratio and the levels of TNF-alpha and IL-6.	Rosuvastatin Calcium	0-12	interleukin 10	Rattus norvegicus	89-94	
20121625-6	2010	Rosuvastatin pretreatment appears to protect these organs after hepatic I/R injury through the reduction of proinflammatory cytokines (TNF-alpha, IL-6, and MCP-1) and stimulation of anti-inflammatory cytokines (IL-10) production.	Rosuvastatin Calcium	0-12	interleukin 10	Rattus norvegicus	211-216	
19147451-7	2009	Furthermore, rosuvastatin reduced the increased IL-6 level and further elevated IL-10 level in the peri-infarct and remote zones of MI.	Rosuvastatin Calcium	13-25	interleukin 10	Rattus norvegicus	80-85	
34226988-7	2021	Beyond lipid lowering, rosuvastatin treatment reduced total and differential WBC counts in the A and AH groups (p<0.05 to p<0.001), IL-6 level in the AH group (p<0.05), and IL-10 level in all treated groups (p<0.05).	Rosuvastatin Calcium	23-35	interleukin 10	Rattus norvegicus	173-178